Recently, the CDE website indicated that Roche Holding Ltd's (RHHBY.US) RO7795068 injection has received approval for clinical trials. The drug is intended for the long-term weight management of adult patients with obesity or who are overweight, in conjunction with dietary control and increased physical activity. Information shows that RO7795068 is a GLP-1R/GIPR dual agonist developed by Carmot. In December 2023, Roche acquired Carmot for $3.1 billion, securing this product. It is reported that the obesity indication for RO7795068 has already advanced to Phase III clinical trials overseas. Phase II results demonstrated that weekly subcutaneous injections of RO7795068 (with doses gradually increased to 24mg) led to a significant weight reduction of 22.5% (estimated efficacy value) in patients, with no weight loss plateau reached at 48 weeks.